Early-phase trial demonstrates shrinkage in pediatric neural tumors

(NIH/National Cancer Institute) In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news